Topics:

Gynecologic Cancers

Targeted Therapy Combo Shows Benefit in Breast and Ovarian Cancer

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients. Image © iQoncept / Shutterstock.com.

Gynecologic Cancers

Preoperative albumin level and number of extended cytoreductive procedures in ovarian cancer patients predicted the likelihood of surgical complications.

The purpose of this paper is to provide a review of site-specific treatment options that involve the targeting of angiogenesis in gynecologic malignancies.

In order for there to be a truly clinically significant breakthrough in targeted therapy, we need to further explore the tumorigenesis of gynecologic malignancies and identify the initiators and true drivers of these cancers.

Survival for women with ovarian cancer has improved since 1975, according to the results of a recent study.

Use of an ovarian cancer risk algorithm that incorporated serum CA-125 screening was able to double the number of invasive epithelial ovarian cancers detected.

The HPV 16/18 vaccine protects women from cervical, anal, and oral HPV infections that can lead to cancer, including some women previously exposed to HPV.

Combination treatment with the PARP inhibitor olaparib plus the PI3K inhibitor BKM120 showed a benefit in subsets of breast cancer and ovarian cancer patients.

Pages

Subscribe to Gynecologic Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.